Level Biotechnology Inc. AI Stock Analysis
Level Biotechnology Inc. (3118) AI Stock Analysis
Level Biotechnology Inc.
(TPEx:3118)
Level Biotechnology scores well on fundamentals and valuation but is held back by technical weakness. The company is effectively debt-free, consistently profitable, and posted record net margins with a 23% increase in net income, while a 12.9 P/E and a 7.26% dividend yield make the shares appealing for income-oriented investors. Offsetting this, revenue has flattened at around NT$737 million, operating cash flow has fallen for three consecutive years, and only about 45% of net income converted to free cash flow. Technically, the stock sits below all key moving averages with a negative MACD, though oversold RSI and Stochastic readings suggest the selling pressure may be stretched. Overall, a low-risk, income-rich holding that needs renewed revenue growth and better cash conversion to re-rate higher.
Level Biotechnology Inc. (3118) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 976.83M
- Dividend Yield
- 7.30%
- Average Volume (3M)
- 16.76K
- Price to Earnings (P/E)
- 12.8
- Beta (1Y)
- 0.12
- Revenue Growth
- -3.54%
- EPS Growth
- 10.34%
- Country
- TW
- Employees
- 128
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Level Biotechnology Inc. Business Overview & Revenue Model
Company Description
Level Biotechnology Inc., founded in 1989 and based in New Taipei City, Taiwan, operates in the commercialization and distribution of scientific products and services. The company supplies specialized reagents and consumables for cell culture, immuno...
Level Biotechnology Inc. Financial Statement Overview
Summary
A conservative, consistently profitable profile. The balance sheet is the standout (score 87): essentially debt-free with NT$8.0 million of debt against NT$580.2 million of equity, two-thirds equity-funded assets, and an improving 13.7% return on equity. The income statement (score 74) shows record net margin of 10.8% and a 23% rise in net income to NT$79.7 million on stable ~33% gross margins, though revenue stalled at NT$736.6 million (roughly flat year over year) after two years of double-digit growth. Cash flow is the weak link (score 59): operating cash flow declined for a third straight year to NT$59.6 million, covering only about three-quarters of net income, and free cash flow of NT$26.9 million — though positive after a heavy 2024 investment year — equals just 45% of earnings.
Income Statement
74PositiveBalance Sheet
87Very PositiveCash Flow
59Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 709.37M | 736.59M | 731.35M | 660.61M | 593.01M | 677.28M |
| Gross Profit | 243.83M | 244.31M | 237.13M | 219.54M | 202.59M | 232.50M |
| EBITDA | 110.31M | 106.00M | 102.62M | 98.70M | 93.00M | 105.06M |
| Net Income | 76.02M | 79.70M | 64.81M | 62.91M | 58.47M | 68.18M |
Balance Sheet | ||||||
| Total Assets | 799.08M | 866.80M | 827.11M | 822.67M | 812.53M | 787.62M |
| Cash, Cash Equivalents and Short-Term Investments | 195.38M | 210.34M | 252.78M | 467.41M | 463.50M | 472.95M |
| Total Debt | 7.38M | 7.98M | 12.68M | 13.50M | 12.73M | 13.36M |
| Total Liabilities | 259.50M | 286.63M | 267.19M | 273.20M | 270.13M | 242.78M |
| Stockholders Equity | 539.58M | 580.18M | 559.91M | 549.47M | 542.40M | 544.84M |
Cash Flow | ||||||
| Free Cash Flow | 77.98M | 26.94M | -159.58M | 62.54M | 58.33M | 146.79M |
| Operating Cash Flow | 93.28M | 59.61M | 64.10M | 70.21M | 65.07M | 155.95M |
| Investing Cash Flow | -18.10M | -38.93M | -216.10M | -10.90M | -10.19M | -8.79M |
| Financing Cash Flow | -134.79M | -63.12M | -62.70M | -55.40M | -64.34M | -54.52M |
Level Biotechnology Inc. Peers Comparison
Overall Rating
- TW:311870Outperform
TW:416049Neutral
TW:417140Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:3118 | 70Outperform | TWD 993.06M | 12.83 | ― | 7.30% | -3.54% | 10.34% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4160 | 49Neutral | TWD 1.00B | 52.56 | ― | 4.93% | 0.10% | -44.49% |
| TW:4171 | 40Underperform | TWD 896.99M | -40.49 | ― | ― | 11.99% | 84.94% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:3118 | Level Biotechnology Inc. | 30.15 | -1.40 | -4.43% | |
| TW:4160 | Genetics Generation Advancement Corp. | 35.55 | -15.42 | -30.26% | |
| TW:4171 | GeneReach Biotechnology Corp. | 15.50 | -5.50 | -26.19% | |
| TW:6810 | Bio Preventive Medicine Corp. | 22.75 | -1.75 | -7.14% | |
| TW:6879 | Tci Gene Inc. | 35.50 | -3.65 | -9.32% | |
| TW:7725 | LabTurbo Biotech Corporation | 21.00 | -1.81 | -7.93% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026